Last reviewed · How we verify
Octohydroaminoacridine Succinate
Octohydroaminoacridine succinate is a cognitive enhancer that likely increases acetylcholine levels in the brain by inhibiting acetylcholinesterase.
Octohydroaminoacridine succinate is a cognitive enhancer that likely increases acetylcholine levels in the brain by inhibiting acetylcholinesterase. Used for Cognitive impairment or dementia (likely indication based on mechanism and phase 3 status).
At a glance
| Generic name | Octohydroaminoacridine Succinate |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Drug class | Acetylcholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
The drug belongs to the acridine class of compounds, which are known acetylcholinesterase inhibitors. By blocking the enzyme that breaks down acetylcholine, it increases cholinergic neurotransmission in the central nervous system, potentially improving cognitive function and memory. This mechanism is similar to other cognitive enhancers used in neurodegenerative diseases.
Approved indications
- Cognitive impairment or dementia (likely indication based on mechanism and phase 3 status)
Common side effects
- Nausea
- Diarrhea
- Cholinergic side effects
Key clinical trials
- Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease (PHASE3)
- Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octohydroaminoacridine Succinate CI brief — competitive landscape report
- Octohydroaminoacridine Succinate updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI